Treatment of severe covid-19 with interleukin 6 receptor inhibition

被引：1
|
作者：
Rajasundaram, Skanda [1 ]
Burgess, Stephen [2 ]
Gill, Dipender [3 ]
机构：
[1] Univ Oxford, Oxford, England
[2] Univ Cambridge, Cambridge, England
[3] Imperial Coll London, Dipender Gill, London SW7 2BX, England
来源：
BMJ MEDICINE | 2022年 / 1卷 / 01期
基金：
英国惠康基金;
关键词：
D O I：
10.1136/bmjmed-2022-000144
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Interleukin 6: A biomarker for COVID-19 progression
    Sebbar E.-H.
    Choukri M.
    [J]. Materials Today: Proceedings, 2023, 72 : 3351 - 3355
  • [22] Interleukin-6 and severe COVID-19: a systematic review and meta-analysis
    Helia Mojtabavi
    Amene Saghazadeh
    Nima Rezaei
    [J]. European Cytokine Network, 2020, 31 : 44 - 49
  • [23] Interleukin-6 and severe COVID-19: a systematic review and meta-analysis
    Mojtabavi, Helia
    Saghazadeh, Amene
    Rezaei, Nima
    [J]. EUROPEAN CYTOKINE NETWORK, 2020, 31 (02) : 44 - 49
  • [24] Interleukin Receptor Antagonists and Janus Kinase Inhibitors Repurposed for Treatment of COVID-19
    Tandon, Nitin
    Luxami, Vijay
    Tandon, Runjhun
    Paul, Kamaldeep
    [J]. MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2022, 22 (21) : 2752 - 2768
  • [25] Are patients with lung cystic fibrosis at increased risk of severe and fatal COVID-19? Interleukin 6 as a predictor of COVID-19 outcomes Reply
    Kosmaczewska, Agata
    Frydecka, Irena
    [J]. POLISH ARCHIVES OF INTERNAL MEDICINE-POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ, 2020, 130 (10): : 920 - 921
  • [26] Criteria for the optimal use of interleukin-6 receptor blockers in patients with COVID-19
    Kruglova, Tatyana S.
    Fomina, Darya S.
    Poteshkina, Nataliya G.
    Frolova, Nadija F.
    Beloglazova, Irina P.
    Mutovina, Zinaida Yu
    Samsonova, Inna, V
    Kovalevskaja, Elena A.
    Zagrebneva, Alena, I
    Serdotetckova, Sofya A.
    Chernov, Anton A.
    Lysenko, Maryana A.
    [J]. TERAPEVTICHESKII ARKHIV, 2021, 93 (11): : 1316 - 1324
  • [27] Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19 REPLY
    Gordon, Anthony C.
    Angus, Derek C.
    Derde, Lennie P. G.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (12): : 1147 - 1149
  • [28] Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality
    Zhang, Chi
    Wu, Zhao
    Li, Jia-Wen
    Zhao, Hong
    Wang, Gui-Qiang
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2020, 55 (05)
  • [29] Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case-control study
    Potere, Nicola
    Di Nisio, Marcello
    Cibelli, Donatella
    Scurti, Rosa
    Frattari, Antonella
    Porreca, Ettore
    Abbate, Antonio
    Parruti, Giustino
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 (02) : 271 - +
  • [30] Assessing the importance of interleukin-6 in COVID-19
    Chen, Luke Y. C.
    Hoiland, Ryan L.
    Stukas, Sophie
    Wellington, Cheryl L.
    Sekhon, Mypinder S.
    [J]. LANCET RESPIRATORY MEDICINE, 2021, 9 (02): : E13 - E13
12345